Y 134

CAS# 849662-80-2

Y 134

Catalog No. BCC7451----Order now to get a substantial discount!

Product Name & Size Price Stock
Y 134: 5mg $115 In Stock
Y 134: 10mg Please Inquire In Stock
Y 134: 20mg Please Inquire Please Inquire
Y 134: 50mg Please Inquire Please Inquire
Y 134: 100mg Please Inquire Please Inquire
Y 134: 200mg Please Inquire Please Inquire
Y 134: 500mg Please Inquire Please Inquire
Y 134: 1000mg Please Inquire Please Inquire
Related Products
  • XMD17-109

    Catalog No.:BCC2061
    CAS No.:1435488-37-1
  • FR 180204

    Catalog No.:BCC3669
    CAS No.:865362-74-9
  • VRT752271

    Catalog No.:BCC4122
    CAS No.:869886-67-9
  • VX-11e

    Catalog No.:BCC2051
    CAS No.:896720-20-0

Quality Control of Y 134

Number of papers citing our products

Chemical structure

Y 134

3D structure

Chemical Properties of Y 134

Cas No. 849662-80-2 SDF Download SDF
PubChem ID 11784736 Appearance Powder
Formula C28H28N2O3S M.Wt 472.6
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO and to 100 mM in ethanol
Chemical Name [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]methanone
SMILES CC(C)N1CCN(CC1)C2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
Standard InChIKey LQEOPHGPHCWOAC-UHFFFAOYSA-N
Standard InChI InChI=1S/C28H28N2O3S/c1-18(2)29-13-15-30(16-14-29)21-7-3-19(4-8-21)27(33)26-24-12-11-23(32)17-25(24)34-28(26)20-5-9-22(31)10-6-20/h3-12,17-18,31-32H,13-16H2,1-2H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Y 134

DescriptionSelective estrogen receptor modulator (SERM) that displays selectivity for ERα over ERβ (Ki values are 0.09 and 11.31 nM respectively) and no cross-reactivity with mineralocorticoid, glucocorticoid, androgen and progesterone receptors. Acts as an agonist in the bone and antagonist in reproductive tissue. Suppresses estrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells.

Y 134 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Y 134 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Y 134

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.116 mL 10.5798 mL 21.1595 mL 42.3191 mL 52.8989 mL
5 mM 0.4232 mL 2.116 mL 4.2319 mL 8.4638 mL 10.5798 mL
10 mM 0.2116 mL 1.058 mL 2.116 mL 4.2319 mL 5.2899 mL
50 mM 0.0423 mL 0.2116 mL 0.4232 mL 0.8464 mL 1.058 mL
100 mM 0.0212 mL 0.1058 mL 0.2116 mL 0.4232 mL 0.529 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Y 134

Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.[Pubmed:24114004]

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):486-93.

PURPOSE: To validate our initial pilot study and confirm sustained safety and tumor response of extended-shelf-life (90)Y glass microspheres. We hypothesized that for the same planned tissue dose, the increase in number of glass microspheres (decayed to the second week of their allowable shelf-life) administered for the same absorbed dose would result in better tumor distribution of the microspheres without causing additional adverse events. METHODS: Between June 2007 and January 2010, 134 patients underwent radioembolization with extended-shelf-life (90)Y glass microspheres; data from 84 new patients were combined with data from our 50-patient pilot study cohort. Baseline and follow-up imaging and laboratory data were obtained 1 and 3 months after therapy and every 3 months thereafter. Clinical and biochemical toxicities were prospectively captured and categorized according to the Common Terminology Criteria. Response in the index lesion was assessed using WHO and EASL guidelines. RESULTS: The mean delivered radiation dose was 123 Gy to the target liver tissue. The mean increase in number of microspheres with this approach compared to standard (90)Y glass microsphere dosimetry was 103%, corresponding to an increase from 3.84 to 7.78 million microspheres. Clinical toxicities included fatigue (89 patients, 66%), abdominal pain (49 patients, 36.6%), and nausea/vomiting (25 patients, 18.7%). Grade 3/4 bilirubin toxicity was seen in three patients (2%). Two (1%) of the initial 50-patient cohort showed gastroduodenal ulcers; gastroduodenal ulcers were not seen in any of the subsequent 84 patients. According to WHO and EASL guidelines, response rates were 48% and 57%, respectively, and 21% demonstrated a complete EASL response. CONCLUSION: This study showed sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres in a larger, 134-patient cohort. The increase in number of microspheres administered theoretically resulted in better tumor distribution of the microspheres without an increase in adverse events.

The second cholesterol oxidase produced by gamma-proteobacterium Y-134.[Pubmed:16233518]

J Biosci Bioeng. 2003;96(3):257-61.

A new strain, Y-134, which was isolated as a producer of cholesterol oxidase (CHO) with high stability in detergents, produced two cholesterol oxidases; one (CHO-A) adsorbed to DEAE-Sepharose, while the other (CHO-U) did not. Specific properties of purified CHO-U were compared with those of CHO-A [Isobe et al., J. Biosci. Bioeng., 95, 257-263 (2003)]. The amino acid sequences of 30 residues from the NH2 terminus were identical in both enzymes, except for one unascertained residue. CHO-U was also stable in nonionic detergents. However, many other properties of CHO-U were different from those of CHO-A; The purified CHO-U exhibited an absorption spectrum characteristic of a flavoprotein with absorption maxima at 276, 350, and 450 nm, and the enzyme activity was not enhanced by metals. CHO-U was a monomeric enzyme with 58 kDa of molecular mass and pI of 7.0. The optimum pH of CHO-U was more than 0.5 acidic pH in relation to that of CHO-A, but the stability of alkaline pH was higher than CHO-A. In addition, the K(m) value for cholesterol was lower than that of CHO-A, and the V(max) value was higher.

Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).[Pubmed:17115070]

Br J Pharmacol. 2007 Jan;150(1):19-28.

BACKGROUND AND PURPOSE: Selective oestrogen receptor (ER) modulators (SERMs) are of great value in the treatment of breast cancer and osteoporosis. The aim of this study was to characterize pharmacologically a new class of SERMs synthesized based on the core structure of raloxifene. EXPERIMENTAL APPROACH: Competitive receptor binding and luciferase-based reporter methods were used to study the bioactivities of raloxifene analogues, followed by efficacy determination in breast cancer cell proliferation assay. ER antagonist effects were investigated in female rats by measuring uterine and mammary gland growth, using wet weight, BrdU incorporation and terminal end bud (TEB) as indicators. KEY RESULTS: Five analogues, belonging to two different structural series and display higher binding affinities for ERalpha than ERbeta were functionally evaluated. One such analogue, Y134, exhibited potent antagonist activity at ERs in CV-1 cells cotransfected with plasmids containing ERalpha or ERbeta and oestrogen-response element-driven luciferase. The estimated IC(50) value was 0.52 nM for ERalpha and 2.94 nM for ERbeta, comparable to that of raloxifene. Little cytotoxicity was observed at Y134 concentrations below 10 microM. Y134 suppressed oestrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells. At an identical dose, administered to ovariectomized rats, Y134 was more effective than raloxifene at arresting oestrogen-induced outgrowth of TEB and mammary gland DNA synthesis, but their inhibitory effects on the uterus were comparable. CONCLUSIONS AND IMPLICATIONS: Y134 is a potent ER antagonist with better mammary gland selectivity than raloxifene and shows potential for development as a new SERM for therapeutic use.

Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.[Pubmed:15713417]

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1505-7.

The synthesis of benzothiophenes containing a piperazine side chain and their binding affinities for estrogen receptors are described. These compounds bearing piperazine side chains were identified to be high-affinity ligands with high selectivity for ER alpha subtype. They were also potent agonists in bone tissue.

Keywords:

Y 134,849662-80-2,Natural Products,Estrogen/progestogen Receptor, buy Y 134 , Y 134 supplier , purchase Y 134 , Y 134 cost , Y 134 manufacturer , order Y 134 , high purity Y 134

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: